

Attorney Docket No.: **DEX-0075**  
Inventors: **Macina and Sun**  
Serial No.: **09/618,596**  
Filing Date: **July 17, 2000**  
Page 2

Please amend claims 1-5 as follows:

1. (amended) A method for diagnosing the presence of colon cancer in a patient comprising:

(a) determining levels of a CSG comprising a polynucleotide sequence or its complement capable of hybridizing under stringent conditions with SEQ ID NO: 1, or a polypeptide encoded thereby, in cells, tissues or bodily fluids in a patient ; and

(b) comparing the determined levels of the CSG with levels of the CSG in cells, tissues or bodily fluids measured in a normal human control, wherein a change in determined levels of the CSG in said patient versus levels of the CSG measured in a normal human control is associated with the presence of colon cancer.

2. (amended) A method of diagnosing metastases of colon cancer in a patient comprising:

(a) identifying a patient having colon cancer that is not known to have metastasized;

(b) determining levels of a CSG comprising a polynucleotide sequence or its complement capable of hybridizing under stringent conditions with SEQ ID NO: 1, or a polypeptide

RECEIVED

JUL 10 2001

TECH CENTER 1600/2900

Attorney Docket No.: **DEX-0075**  
Inventors: **Macina and Sun**  
Serial No.: **09/618,596**  
Filing Date: **July 17, 2000**  
Page 3

encoded thereby, in a first sample of cells, tissues or bodily fluid from said patient; and

(c) comparing the determined levels of the CSG with levels of the CSG measured in a second sample of cells, tissues or bodily fluid from a normal human control, wherein an increase in determined levels of the CSG in the first sample as compared to the second sample is associated with a cancer that has metastasized.

31

3. (amended) A method of staging colon cancer in a patient having colon cancer comprising:

(a) identifying a patient having colon cancer;  
(b) determining levels of a CSG comprising a polynucleotide sequence or its complement capable of hybridizing under stringent conditions with SEQ ID NO: 1, or a polypeptide encoded thereby, in a first sample of cells, tissues or bodily fluid from said patient; and

(c) comparing the determined levels of the CSG with levels of the CSG measured in a second sample of cells, tissues or bodily fluid from a normal human control, wherein an increase in the determined levels of the CSG in the first sample as compared to the second sample is associated with a cancer that is progressing and a decrease in the determined levels of the CSG in the first

Ab  
C  
W

Attorney Docket No.: **DEX-0075**  
Inventors: **Macina and Sun**  
Serial No.: **09/618,596**  
Filing Date: **July 17, 2000**  
Page 4

*Prob C*  
sample as compared to the second sample is associated with a cancer that is regressing or in remission.

4. (amended) A method of monitoring colon cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having colon cancer that is not known to have metastasized;

*Sub E1*  
(b) periodically determining levels of a CSG comprising a polynucleotide sequence or its complement capable of hybridizing under stringent conditions with SEQ ID NO: 1, or a polypeptide encoded thereby, in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined levels of the CSG with levels of the CSG measured in cells, tissues or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined levels of the CSG in the patient versus the normal human control is associated with a cancer that has metastasized.

5. (amended) A method of monitoring a change in stage of colon cancer in a patient comprising:

(a) identifying a patient having colon cancer;